19 November2026: Sonesitatug vedotin granted priority review in the US for 2nd and later-line treatment of patients with CLDN18.2+ advanced gastric/GEJ cancers
AstraZeneca’s biologics license application forsonesitatugvedotin has been accepted and granted Priority Review by the US FDA for the second- and later-line treatment of adults with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma expressing CLDN18.2 on at least 25% of tumour cells at any staining intensity. the FDA decision is expected in Q2 2027
The BLA is supported by the phase III CLARITY-Gastric01trial, which demonstrated a42% reduction in the risk of death with Sone-Ve compared with investigator’s choice of therapyOS HR 0.58. Median overall survival was 10.6 months versus 6.4 months, respectively. The survival benefit was consistent across predefined subgroups, including patients with lower and higher CLDN18.2 expression
The application addresses a significant unmet need in uterine carcinosarcoma, an aggressive and rare form of endometrial cancer associated with poor prognosis and high recurrence rates. currently, treatment relies largely on chemotherapy, with recurrence reported in 57% of patients, highlighting the need for targeted treatment approaches, particularly in the advanced or recurrent setting
Sonesitatug vedotin is a CLDN18.2-targeted antibody-drug conjugate (ADC) that delivers a cytotoxic payload directly to CLDN18.2-expressing tumour cells, promoting tumour-cell death. It represents a targeted therapeutic approach and a potential alternative to conventional chemotherapy in advanced gastric and GEJ cancers
Sone-Ve could establish AstraZeneca’s position in the CLDN18.2-targeted gastric cancer market, with an estimated 7,500 US patients treated annually in the second- and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancer. the therapy has received Orphan Drug Designation from the US FDA and European Commission, as well as Breakthrough Designation in China for second-line gastric cancer. regulatory applications are also under review in the EU, China and other markets